Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB26FNMNN
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,565
Award facts
- Contract value 100% obligated
- $9,564.66 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,564.66 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The contract is a firm fixed-price delivery order with an ultimate completion date of November 5, 2025, and was executed without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group will perform the work at its Park Ridge facility and serve as the prime contractor with no identified subcontractor relationships.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to provide recurring pharmaceutical supplies to Department of Defense military healthcare facilities worldwide. The underlying IDC, valued at $499,999,999, was awarded on November 13, 2025, with a completion date of December 31, 2036, and includes a 30-month base period with three 30-month option periods. Through this master contract vehicle, DMS Pharmaceutical Group has demonstrated substantial federal contracting activity and capability to supply a comprehensive range of products including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals critical to military medical operations.
Quick answers
Who was awarded contract SPE2DB26FNMNN?
SPE2DB26FNMNN was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DB26FNMNN worth?
The government has obligated $9,565 on SPE2DB26FNMNN.
Is contract SPE2DB26FNMNN an order under another contract?
Yes. SPE2DB26FNMNN is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMNN competed?
The extent of competition for SPE2DB26FNMNN was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award